The prominent European conference for Health Economics and Outcomes Research (HEOR), ISPOR Europe 2021, is around the corner. As always, we are excited about Cytel’s presence at this year’s virtual conference. Cytel’s Global HEOR & RWE experts will be contributing to a range of sessions at the event, taking place November 30th - December 3rd. Our global team of consultants will deliver several On Demand Podium Sessions, Issue Panel and Workshop, and Poster presentations to showcase their work and share innovative insights in HEOR, Real World Data, the impact of the COVID-19 pandemic, HTAs, and more. These presentations will also cover a broad range of therapeutic areas including, oncology, respiratory related disorders, and mental health, among others.
Here is a brief overview of an ISPOR Europe Workshop that is going to be led by Radek Wasiak, PhD, Chief Data Officer & Head of Europe at Cytel:
102WK: Can We ‘Borrow’ Real World Outcomes? What Can We Leverage from Chinese and US Data When Assessing Real World Outcomes for HTA Agreements for Rare Diseases in Europe?
The aim of this ISPOR Workshop is to explore the conditions and methods under which real-world data on rare diseases may be robustly borrowed from sources in US and China, given the known limitations of European country-specific sources.
Randomized controlled trials have short time-horizons, and large sample sizes or randomized comparators are not always feasible in rare disease settings. Thus, the evidence base increasingly being presented to payers for these conditions can be inadequate to robustly determine clinical and cost-effectiveness. This uncertainty can delay critical decisions on reimbursement, impacting patient access.
While “value-based” arrangements can be made between payers and manufacturers, establishing real-world outcomes for rare conditions remains challenging. HTA submission in Europe that aims to leverage real world outcomes faces several key questions: Can outcomes based on small numbers of patients be trusted? How can this be used to reliably address uncertainties in evidence?
During this workshop, the moderator will describe the problem and illustrate how US data have been used to support post-authorization safety mandates in Europe. This will open the discussion on conditions under which US data can serve as a benchmark for real world outcome evaluations in Europe. The available methodological approaches will also be presented and reviewed during this session.
Cytel’s experts in HEOR specialize in health economic modeling, HEOR value communication, and other standard models of pharmaceutical modeling for comparative effectiveness research. You can experience their unrivalled knowledge and expertise in advanced analytics, innovative methods, and technical excellence by attending the Cytel sessions at Virtual ISPOR 2021.
Click below to download Cytel’s full list of sessions at the event and share this brochure with your colleagues who may be interested.
About the Author of Blog:
Mansha Sachdev specializes in content creation and knowledge management. She holds an MBA degree and has 11 years of experience in handling various facets of marketing, across industries. At Cytel, Mansha is a Content Marketing Manager and is responsible for producing informative content that is related to the pharmaceutical and medical devices industries.
